ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,626,349 | +144.7% | 317,963 | +181.2% | 0.00% | +100.0% |
| Q2 2023 | $2,708,338 | +21.6% | 113,083 | -4.5% | 0.00% | 0.0% |
| Q1 2023 | $2,227,855 | +905.0% | 118,377 | +750.2% | 0.00% | – |
| Q4 2022 | $221,670 | -79.7% | 13,924 | -79.1% | 0.00% | – |
| Q3 2022 | $1,092,000 | +26.1% | 66,744 | +8.5% | 0.00% | – |
| Q2 2022 | $866,000 | -86.5% | 61,498 | -76.7% | 0.00% | -100.0% |
| Q1 2022 | $6,396,000 | -47.4% | 264,076 | -49.3% | 0.00% | -25.0% |
| Q4 2021 | $12,160,000 | +355.4% | 520,962 | +224.0% | 0.00% | – |
| Q3 2021 | $2,670,000 | -62.4% | 160,782 | -44.7% | 0.00% | -100.0% |
| Q2 2021 | $7,097,000 | -63.9% | 290,943 | -61.8% | 0.00% | -70.0% |
| Q1 2021 | $19,649,000 | +90.5% | 761,582 | +294.8% | 0.01% | +100.0% |
| Q4 2020 | $10,312,000 | +7.6% | 192,892 | -16.9% | 0.01% | -16.7% |
| Q3 2020 | $9,580,000 | -33.8% | 232,225 | -22.2% | 0.01% | -45.5% |
| Q2 2020 | $14,463,000 | +540.0% | 298,408 | +457.8% | 0.01% | +450.0% |
| Q1 2020 | $2,260,000 | +16.1% | 53,500 | +17.6% | 0.00% | -33.3% |
| Q4 2019 | $1,947,000 | -37.7% | 45,509 | -47.6% | 0.00% | -40.0% |
| Q3 2019 | $3,126,000 | +117.1% | 86,871 | +61.2% | 0.01% | +66.7% |
| Q2 2019 | $1,440,000 | -39.8% | 53,876 | -39.5% | 0.00% | -25.0% |
| Q1 2019 | $2,392,000 | +69.6% | 89,098 | +2.2% | 0.00% | +33.3% |
| Q4 2018 | $1,410,000 | -47.0% | 87,180 | -32.0% | 0.00% | -50.0% |
| Q3 2018 | $2,660,000 | +272.5% | 128,165 | +174.4% | 0.01% | +200.0% |
| Q2 2018 | $714,000 | -7.9% | 46,703 | +35.4% | 0.00% | -33.3% |
| Q1 2018 | $775,000 | +10.4% | 34,493 | +48.0% | 0.00% | +50.0% |
| Q4 2017 | $702,000 | +166.9% | 23,300 | +233.9% | 0.00% | +100.0% |
| Q3 2017 | $263,000 | -60.7% | 6,979 | -71.0% | 0.00% | -50.0% |
| Q2 2017 | $670,000 | -4.4% | 24,042 | +17.9% | 0.00% | -33.3% |
| Q1 2017 | $701,000 | -90.0% | 20,400 | -91.6% | 0.00% | -90.0% |
| Q4 2016 | $7,017,000 | +1513.1% | 243,298 | +1680.3% | 0.03% | +1400.0% |
| Q3 2016 | $435,000 | -73.6% | 13,666 | -73.1% | 0.00% | -75.0% |
| Q2 2016 | $1,649,000 | -66.6% | 50,810 | -71.2% | 0.01% | -71.4% |
| Q1 2016 | $4,939,000 | +212.2% | 176,661 | +298.2% | 0.03% | +180.0% |
| Q4 2015 | $1,582,000 | +68.1% | 44,368 | +97.4% | 0.01% | +66.7% |
| Q2 2015 | $941,000 | -31.6% | 22,472 | -46.8% | 0.01% | -40.0% |
| Q1 2015 | $1,376,000 | – | 42,211 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |